# Kymera Therapeutics, Inc. Common Stock (KYMR) — Stock CV

Kymera Therapeutics, Inc. is a $9.35B healthcare company. Revenue grew 134.8% over the last year, it currently loses money, and it holds more cash than debt.

> Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives.

## Identity

- **Ticker**: KYMR
- **Sector**: Healthcare
- **Industry**: Biological Products, (No Diagnostic Substances)
- **Headquarters**: WATERTOWN, MA
- **Employees**: 273
- **Website**: https://www.kymeratx.com
- **Market cap**: $9.35B
- **Last price**: $112.40
- **Financial profile**: Strong

## Vitals (TTM)

- **Revenue**: $105M
- **Net income**: -$300M
- **Free cash flow**: -$238M
- **Net cash**: $766M
- **Revenue growth (YoY)**: 134.8%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 20 |
| Growth | 0 |
| Profitability | 0 |
| Health | 75 |
| Quality | 17 |
| Moat | 0 |

## Qualifications (beginner checklist) — 4 of 9 passed

- [x] Revenue growing — +134.8% YoY
- [ ] Profitable — -$300M TTM
- [ ] Profit growing — -39.1% YoY
- [ ] Generates cash — -$238M TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $9.35B market cap
- [ ] Not printing shares — +64.1% shares over ~5y
- [ ] Proven track record — 0/6 profitable years
- [x] Financially stable — Altman Z 47.7 — safe

## Strengths

- Revenue growing 134.8% year over year
- Net cash position after subtracting debt from cash
- Altman Z-Score 47.67 — low bankruptcy-risk zone

## Watch-outs

- Not profitable — 285.3% net margin
- Negative free cash flow (-$238.0M)
- Thin interest coverage (-1072.5×)
- Loss-making in 6 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $72.8M | -$100M | -$131M |
| FY2022 | $46.8M | -$155M | -$156M |
| FY2023 | $78.6M | -$147M | -$137M |
| FY2024 | $47.1M | -$224M | -$207M |
| FY2025 | $39.2M | -$311M | -$234M |

---

Source: https://stockcv.com/KYMR — derived from company filings; may be delayed or incomplete. Information, not investment advice.